Novel hormone essential for heart development discovered

December 6, 2013

Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases. The hormone - which they have chosen to name ELABELA - is only 32 amino-acids long, making it amongst the tiniest proteins made by the human body.

The team led by Dr Bruno Reversade carried out experiments to determine ELABELA's function, since its existence was hitherto unsuspected. Using zebrafish designed to specifically lack this hormone, they uncovered that ELABELA is indispensable for heart formation. Zebrafish embryos without this gene had rudimentary or no heart at all (see Figure 1). Their results were published in the 5 December 2013 online issue of Developmental Cell.

Deficiencies in hormones are the cause of many diseases, such as the loss of insulin or insulin resistance, that results in diabetes, and irregularities in appetite and satiety hormones that can cause obesity. Hormones are known to control functions such as sleep, appetite and fertility. However, this is the first time that scientists have revealed the existence of a conserved[1] hormone playing such an early role during embryogenesis, effectively orchestrating the development of an entire organ.

The team also found that ELABELA uses a receptor previously believed to be specific to APELIN, a blood-pressure controlling hormone. This receptor called APJ or Apelin Receptor has dual functions - it first conveys signals from ELABELA and then from APELIN. Mutations in the Apelin Receptor also prevent the heart from forming. Zebrafish bereft of the Apelin Receptor are referred to as the Grinch, in reference to the cold and heartless cartoon character created by Dr. Seuss in 1957.

ELABELA has also been found to be expressed in human embryonic stem cells[2], indicating that it might have other functions beyond its role in cardiovascular development.

The team's findings hold great promise for the potential use of ELABELA as a therapeutic molecule for cardiovascular disease to be used in cardiac repair and control of hypertension. As some people might have a harmful copy of the ELABELA gene in their genetic make-up, sequencing and screening for this particular gene in the general population might also help to detect predisposition to anomalies before the disease progresses.

Dr Bruno Reversade said, "The human genome has been sequenced over a decade ago. That we can still find anonymous hormones charms me. There are a still a few more to discover…but not for long."

Prof Birgitte Lane, Executive Director of IMB, said, "This discovery shows great promise for the development of targeted therapies for and in the future. It is an excellent example of how basic research can lead to surprising and unexpected findings that may change and refine medical practice."

Prof Hong Wan Jin, Executive Director of IMCB, said, "I am very pleased with Bruno's achievement as it reflects the synergy of collaboration and joint efforts among various research institutes in Singapore."

Explore further: Apelin hormone injections powerfully lower blood sugar

More information: "ELABELA: A Hormone Essential for Heart Development Signals via the Apelin Receptor." Serene C. Chng, Lena Ho, Jing Tian, Bruno Reversade. Developmental Cell, 5 December 2013. DOI: 10.1016/j.devcel.2013.11.002

Related Stories

Apelin hormone injections powerfully lower blood sugar

November 4, 2008

By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice. The findings suggest that ...

Understanding the APJ Receptor Binding Site

June 1, 2010

(PhysOrg.com) -- Apelin is a recently discovered peptide that binds to the apelin (or APJ) G-protein-coupled receptor. Apelin-13 (NH2-QRPRLSHKGPMPF-COOH), one of several cleavage products of the proprotein form of the apelin ...

New class of drug targets heart disease

September 17, 2013

(Edmonton) Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

Recommended for you

New method creates endless supply of kidney precursor cells

August 25, 2016

Salk Institute scientists have discovered the holy grail of endless youthfulness—at least when it comes to one type of human kidney precursor cell. Previous attempts to maintain cultures of the so-called nephron progenitor ...

Strict diet combats rare progeria aging disorders

August 25, 2016

Mice with a severe aging disease live three times longer if they eat thirty percent less. Moreover, they age much healthier than mice that eat as much as they want. These are findings of a joint study being published today ...

New avenue for understanding cause of common diseases

August 25, 2016

A ground-breaking Auckland study could lead to discoveries about many common diseases such as diabetes, cancer and dementia. The new finding could also illuminate the broader role of the enigmatic mitochondria in human development.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.